Company-specific bad news kept these stocks out of the rally.
News & Analysis: Amneal Pharmaceuticals, Inc.
Stubborn headwinds in the generic-drug markets are forcing the company to restructure operations.
The industry drew the ire of 44 state attorneys general alleging widespread conspiracy to inflate drug prices.
AMRX earnings call for the period ending March 31, 2019.
Investors were none too pleased with Amneal's first-quarter performance. Here's why.
AMRX earnings call for the period ending December 31, 2018.
AMRX earnings call for the period ending September 30, 2018.
The hits keep coming for this generic-drug manufacturer.
The company snagged a huge supply contract with Jerome Stevens Pharmaceuticals.